The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Osteosarcoma


Psychiatry related information on Osteosarcoma


High impact information on Osteosarcoma

  • Expression of wild-type, but not mutant, DOCK4 in mouse osteosarcoma cells with a deletion of the endogenous gene suppresses growth in soft agar and tumor invasion in vivo [8].
  • The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P = 0.002) [9].
  • Using DNA transfection, we show that TGF-beta stimulates the activity of the mouse alpha 2(l) collagen promoter 5- to 10-fold in mouse NIH 3T3 and rat osteosarcoma cells [10].
  • However, HTLV-I-infected human osteosarcoma cells do not express IL2R alpha-CAT constructs [11].
  • A 140 kd protein was bound by the affinity matrix from octylglucoside extracts of MG-63 human osteosarcoma cells and specifically eluted with the synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro [12].

Chemical compound and disease context of Osteosarcoma


Biological context of Osteosarcoma


Anatomical context of Osteosarcoma


Gene context of Osteosarcoma


Analytical, diagnostic and therapeutic context of Osteosarcoma


  1. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S.M., Helman, L.J. Nat. Med. (2004) [Pubmed]
  2. Preferential germline mutation of the paternal allele in retinoblastoma. Zhu, X.P., Dunn, J.M., Phillips, R.A., Goddard, A.D., Paton, K.E., Becker, A., Gallie, B.L. Nature (1989) [Pubmed]
  3. Cycloheximide-dependent reversion of human cells transformed by MSV and chemical carcinogen. Cho, H.Y., Rhim, J.S. Science (1979) [Pubmed]
  4. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Giovannini, M., Robanus-Maandag, E., van der Valk, M., Niwa-Kawakita, M., Abramowski, V., Goutebroze, L., Woodruff, J.M., Berns, A., Thomas, G. Genes Dev. (2000) [Pubmed]
  5. Cytocidal effect of purified human fibroblast interferon on tumor cells in vitro. Ito, M., Buffett, R.F. J. Natl. Cancer Inst. (1981) [Pubmed]
  6. Identification and characterization of valosin-containing protein (VCP/p97) in untransformed osteoblast-like cells. Behnam, K., Murray, S.S., Brochmann, E.J. J. Orthop. Res. (2005) [Pubmed]
  7. Proceedings of the Osteosarcoma Study Group Meeting (Bethesda, Maryland, January 19, 1977): introduction: treatment of osteogenic sarcoma. Muggia, F.M., Handelsman, H. Cancer treatment reports. (1978) [Pubmed]
  8. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Yajnik, V., Paulding, C., Sordella, R., McClatchey, A.I., Saito, M., Wahrer, D.C., Reynolds, P., Bell, D.W., Lake, R., van den Heuvel, S., Settleman, J., Haber, D.A. Cell (2003) [Pubmed]
  9. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M.C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M. N. Engl. J. Med. (1995) [Pubmed]
  10. A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Rossi, P., Karsenty, G., Roberts, A.B., Roche, N.S., Sporn, M.B., de Crombrugghe, B. Cell (1988) [Pubmed]
  11. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cross, S.L., Feinberg, M.B., Wolf, J.B., Holbrook, N.J., Wong-Staal, F., Leonard, W.J. Cell (1987) [Pubmed]
  12. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Pytela, R., Pierschbacher, M.D., Ruoslahti, E. Cell (1985) [Pubmed]
  13. Methotrexate as adjuvant treatment for primary osteosarcoma. Edmonson, J.H., Green, S.J., Ivins, J.C., Gilchrist, G.S., Cregan, E.T., Pritchard, D.J., Smithson, W.A., Dahlin, D.C., Taylor, W.F. N. Engl. J. Med. (1980) [Pubmed]
  14. Identification and isolation of a membrane protein necessary for leukotriene production. Miller, D.K., Gillard, J.W., Vickers, P.J., Sadowski, S., Léveillé, C., Mancini, J.A., Charleson, P., Dixon, R.A., Ford-Hutchinson, A.W., Fortin, R. Nature (1990) [Pubmed]
  15. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Komm, B.S., Terpening, C.M., Benz, D.J., Graeme, K.A., Gallegos, A., Korc, M., Greene, G.L., O'Malley, B.W., Haussler, M.R. Science (1988) [Pubmed]
  16. A parathyroid hormone-like protein from cultured human keratinocytes. Merendino, J.J., Insogna, K.L., Milstone, L.M., Broadus, A.E., Stewart, A.F. Science (1986) [Pubmed]
  17. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Gyory, I., Wu, J., Fejér, G., Seto, E., Wright, K.L. Nat. Immunol. (2004) [Pubmed]
  18. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Orosco, A., Fromigué, O., Bazille, C., Entz-Werle, N., Levillain, P., Marie, P.J., Modrowski, D. Cancer Res. (2007) [Pubmed]
  19. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Gordon, N., Koshkina, N.V., Jia, S.F., Khanna, C., Mendoza, A., Worth, L.L., Kleinerman, E.S. Clin. Cancer Res. (2007) [Pubmed]
  20. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo. Brounais, B., Chipoy, C., Mori, K., Charrier, C., Battaglia, S., Pilet, P., Richards, C.D., Heymann, D., Rédini, F., Blanchard, F. Clin. Cancer Res. (2008) [Pubmed]
  21. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Bruheim, S., Xi, Y., Ju, J., Fodstad, O. Clin. Cancer Res. (2009) [Pubmed]
  22. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. He, B.C., Chen, L., Zuo, G.W., Zhang, W., Bi, Y., Huang, J., Wang, Y., Jiang, W., Luo, Q., Shi, Q., Zhang, B.Q., Liu, B., Lei, X., Luo, J., Luo, X., Wagner, E.R., Kim, S.H., He, C.J., Hu, Y., Shen, J., Zhou, Q., Rastegar, F., Deng, Z.L., Luu, H.H., He, T.C., Haydon, R.C. Clin. Cancer Res. (2010) [Pubmed]
  23. Phage display-derived peptides for osteosarcoma imaging. Sun, X., Niu, G., Yan, Y., Yang, M., Chen, K., Ma, Y., Chan, N., Shen, B., Chen, X. Clin. Cancer Res. (2010) [Pubmed]
  24. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Thomas, D.M., Carty, S.A., Piscopo, D.M., Lee, J.S., Wang, W.F., Forrester, W.C., Hinds, P.W. Mol. Cell (2001) [Pubmed]
  25. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Pollak, M., Sem, A.W., Richard, M., Tetenes, E., Bell, R. J. Natl. Cancer Inst. (1992) [Pubmed]
  26. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. Thomas, D.M., Johnson, S.A., Sims, N.A., Trivett, M.K., Slavin, J.L., Rubin, B.P., Waring, P., McArthur, G.A., Walkley, C.R., Holloway, A.J., Diyagama, D., Grim, J.E., Clurman, B.E., Bowtell, D.D., Lee, J.S., Gutierrez, G.M., Piscopo, D.M., Carty, S.A., Hinds, P.W. J. Cell Biol. (2004) [Pubmed]
  27. Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Buckbinder, L., Talbott, R., Seizinger, B.R., Kley, N. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  28. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Heldin, C.H., Johnsson, A., Wennergren, S., Wernstedt, C., Betsholtz, C., Westermark, B. Nature (1986) [Pubmed]
  29. Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. Pauli, B.U., Memoli, V.A., Kuettner, K.E. J. Natl. Cancer Inst. (1981) [Pubmed]
  30. Circulating immune complexes in human osteosarcoma. Tsang, K.Y., Singh, I., Blakemore, W.S. J. Natl. Cancer Inst. (1979) [Pubmed]
  31. Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. Regulation of PC-1 expression in osteosarcoma cells by transforming growth factor-beta. Huang, R., Rosenbach, M., Vaughn, R., Provvedini, D., Rebbe, N., Hickman, S., Goding, J., Terkeltaub, R. J. Clin. Invest. (1994) [Pubmed]
  32. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. Van Damme, J., Proost, P., Lenaerts, J.P., Opdenakker, G. J. Exp. Med. (1992) [Pubmed]
  33. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Brown, D.R., Deb, S., Muñoz, R.M., Subler, M.A., Deb, S.P. Mol. Cell. Biol. (1993) [Pubmed]
  34. Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases. Siitonen, H.A., Kopra, O., Kääriäinen, H., Haravuori, H., Winter, R.M., Säämänen, A.M., Peltonen, L., Kestilä, M. Hum. Mol. Genet. (2003) [Pubmed]
  35. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Wang, I.C., Chen, Y.J., Hughes, D., Petrovic, V., Major, M.L., Park, H.J., Tan, Y., Ackerson, T., Costa, R.H. Mol. Cell. Biol. (2005) [Pubmed]
  36. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Walkley, C.R., Qudsi, R., Sankaran, V.G., Perry, J.A., Gostissa, M., Roth, S.I., Rodda, S.J., Snay, E., Dunning, P., Fahey, F.H., Alt, F.W., McMahon, A.P., Orkin, S.H. Genes Dev. (2008) [Pubmed]
  37. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Toffoli, G., Biason, P., Russo, A., De Mattia, E., Cecchin, E., Hattinger, C.M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., Picci, P., Serra, M. Clin. Cancer Res. (2009) [Pubmed]
  38. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Patiño-García, A., Zalacain, M., Folio, C., Zandueta, C., Sierrasesúmaga, L., San Julián, M., Toledo, G., De Las Rivas, J., Lecanda, F. Clin. Cancer Res. (2009) [Pubmed]
  39. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Pahl, J.H., Ruslan, S.E., Buddingh, E.P., Santos, S.J., Szuhai, K., Serra, M., Gelderblom, H., Hogendoorn, P.C., Egeler, R.M., Schilham, M.W., Lankester, A.C. Clin. Cancer Res. (2012) [Pubmed]
  40. The role of methotrexate in osteosarcoma. Grem, J.L., King, S.A., Wittes, R.E., Leyland-Jones, B. J. Natl. Cancer Inst. (1988) [Pubmed]
  41. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. Chan, H.S., Grogan, T.M., Haddad, G., DeBoer, G., Ling, V. J. Natl. Cancer Inst. (1997) [Pubmed]
  42. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. Sekyi-Otu, A., Bell, R., Andrulis, I., Pollak, M. J. Natl. Cancer Inst. (1994) [Pubmed]
WikiGenes - Universities